Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02053636 | A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer | PHASE2 | COMPLETED | 76 | — | — | Dec 1, 2013 | Apr 4, 2017 | Jul 25, 2024 | 29 | Australia, Belgium +7 |
Tumor evaluation every 8 weeks throughout the study
| Arm | Type | Description |
|---|---|---|
| lucitanib | EXPERIMENTAL | Hard gelatine capsules of 2,5, 5 and 10 mg or film coated tablets of 5 and 7,5 mg. 5 to 10 mg orally on a daily basis until unacceptable toxicity according to the investigator, disease progression or withdrawal of consent |
| Name | Type | Description |
|---|---|---|
| lucitanib | DRUG | - |
Inclusion Criteria: * Histologically confirmed breast adenocarcinoma. * Presence of an accessible metastatic lesion for biopsy or at least one archived metastatic tumour sample. * Prior first-line systemic therapy in the metastatic setting. * Demonstrated progression of disease by radiological or c...